The efficacy of preemptive therapy was evaluated in bone marrow transplantation (BMT) recipients associated with Chagas disease (CD). The criterion to include patients in the protocol was the serological reactivity for CD in recipients and/or donors before transplant. After BMT, the monitoring was performed using the direct Strout method (SM), which detects clinical levels of Trypanosome cruzi parasitemia, and CD conventional serological tests. Monitoring took place during 60 days in ABMT and throughout the immunosuppressive period in allogeneic BMT. Reactivation of CD was diagnosed by detecting T. cruzi parasites in blood or tissues. In primary T. cruzi infection, an additional diagnostic criterion was the serological conversion. A total of 25 CD-BMT patients were included. Two ABMT and four allogeneic BMT recipients showed CD recurrences diagnosed by SM. One patient also showed skin lesions with T. cruzi amastigotes. Benznidazole treatment (Roche Lab), an antiparasitic drug, was prescribed at a dose of 5 mg/kg/day during 4-8 weeks with recovery of patients. Primary T. cruzi infection was not observed. This report proves the relevance of monitoring CD in BMT patients and demonstrates that preemptive therapy was able to abrogate the development of clinical and systemic disease.
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Chagas disease (CD) is caused by Trypanosome cruzi, an obligate protozoan, which affects around 25% of the population in Latin America. 1 In Argentina, it is estimated that 2 000 000 people are infected and around 600 000 could present clinical abnormalities consistent with chronic CD. 2 This disease also affects human beings in industrialized countries due to migration of people who move from endemic areas looking for better living conditions. Human transmission in rural areas in endemic countries is mainly through triatomine insect bites, but in urban areas in either endemic or nonendemic countries, T. cruzi infection occurs through blood transfusions or occasionally organ transplants. 3, 4 The reactivation of CD revealed as a febrile syndrome sometimes accompanied by skin manifestations, myocarditis and meningoencephalitis, has been associated with immunosuppressive states such as those induced by hematological malignancies, 5 corticosteroid therapy, 6 kidney 7 and heart transplantation 8 and AIDS. 9 In recent preliminary studies, we have described 10,11 the outcome of CD in bone marrow transplantation (BMT) patients. In the present prospective study, we have evaluated the effectiveness and safety of preemptive therapy in our whole BMT and CD patient population in order to demonstrate whether this approach was able to abrogate the development of clinical and systemic disease. This study involved a cohort of CD patients who underwent BMT in four health centers in Argentina using the same monitoring strategy.
Patients and methods
All patients were submitted to BMT, between 1989 and December 2002, in ICTEM Sanatorio Anta´rtida, Clı´nica Privada Independencia, Instituto Alexander Flemming and Hospital Brita´nico, health care centers of Buenos Aires, Argentina. All patients were evaluated for CD through serological screening before starting conditioning chemotherapy and transplant. The serological reactivity against T. cruzi both in recipients and/or donors was the inclusion criterion to incorporate those recipients in the CD protocol. CD screening was performed by means of three serological methods such as indirect immunofluorescence assay (IFA), indirect hemagglutination (IHA) and immunoenzyme assay or ELISA. Serological titers X1/32 for IFA and IHA and an optical density X0.20 at 490 nm for ELISA were considered reactive for CD. Those methods were standardized in the Fatala Chabe´n Institute, and sensitivity and specificity were frequently reported. 12, 13 According to the WHO criteria, at least two of three specific serological tests must be reactive to consider a patient infected with T. cruzi. Additionally, all CD patients under immunosuppression for underlying diseases and therefore at risk of reactivation were screened through the direct Strout method (SM) before BMT. Recipients and donors were also evaluated via chest X-ray, EKG, echocardiogram and clinical methods to rule out clinical evidence of chronic CD. In addition, recipients and donors were studied according to routine protocols applied in BMT.
After BMT, the monitoring was performed using parasitological and serological methods. Parasitological studies were performed using direct SM, a fast and highly sensitivity method that detects high levels of parasitemia through parasite concentration by double centrifugation, 14 indicative of clinical or subclinical acute phase. The usefulness of SM has been demonstrated in other types of transplants. 15 In the initial stages of the study, enriched and indirect parasitological methods, such as blood cultures 16 and xenodiagnosis, 17 were also used in this protocol for detecting low levels of T. cruzi parasitemia. Serological studies were carried out according to the above-mentioned procedures in all CD and non-CD recipients who received BMT from infected donors.
The recipients were checked on a weekly basis using SM and serological methods during the first 2 months, every 15 days during the third month and through monthly controls from then on. Monitoring took place throughout the immunosuppressive period after allogenic (Allo) BMT, and during the 60 days in ABMT. However, the CD protocol returned to a weekly frequency in every instance of clinical suspicion that an infectious episode was in course and until the etiological cause was diagnosed.
Criteria to diagnose reactivation of CD or primary T. cruzi infection transmitted through the bone marrow was evidence of parasites by direct methods such as in blood by SM, by direct observation in CSF when neurological signs were present, or in tissue via skin, heart, or CNS biopsies or any other organ involvement when signs of reactivation were present. In cases of transmission of T. cruzi infection, serological conversion was an additional diagnostic criterion.
Preemptive therapy with benznidazole (BZ) (Roche Lab. 100 mg/pill) was prescribed to those patients with CD reactivation or primary infection at a dose of 5 mg/kg/day, two times per day, for at least 4 weeks and to a maximum of 8 weeks according to the recommendation of the Ministry of Health of Argentina. 18 The effectiveness of treatment was determined by abrogation of parasitemia, being negative for SM, and/or regression of tissue lesions.
The CD protocol was approved by the Bio-Ethics Committee of the National Administration of Health Institutes and Laboratories CG Malbra´n. Informed consent was obtained from all patients in local health institutions.
Four groups of BMT patients with CD were considered: (I) ABMT-CD recipients; (II) Allo, CD recipients, non-CD donors; (III) Allo, CD recipients and donors and (IV) Allo non-CD recipients, CD donors.
Results
We evaluated 1328 BMT, 441 Allo and 887 ABMT patients between 1989 and December 2002. Table 1 shows the demographics of patients from the four collaborating centers. (9) 34 (15) 65 (6) Chagas disease patients (%) 9 (2.2) 3 (0.6) 11 (3.7) 2 (0.9) 25 (1.9)
The incidence rate of CD in our study was 1.9% (25/ 1328) with a range of 0.6-3.7%. All CD patients were in indeterminate phase of CD, that is, they did not show any of the radiological, electrocardiological or clinical abnormalities of chronic CD.
Group I
A total of 12 ABMT-CD recipients were included (Table 2) . Two patients were considered to have relapsed CD; in the other 10 recipients, neither reactivation of parasitemia nor clinical signs were diagnosed during the follow-up.
Patient #1 was a 31 year-old male with non-Hodgkin's lymphoma who underwent ABMT in August 1993. T. cruzi parasitemia was detected only by blood cultures 4 days before bone marrow infusion during the running neutropenic period, without signs or symptoms of CD reactivation. Preemptive therapy with BZ was started and administered during 30 days. The investigation of T. cruzi parasites in the infused bone marrow was negative. During weekly controls, the parasitemia was always negative using SM. After treatment, the patient did not show any signs of relapsing T. cruzi parasitemia or CD.
Patient #10, a 48 year-old male with non-Hodgkin's lymphoma, was included in the study in March 2000. After chemotherapy treatment for underlying disease, at ABMT -20 days, parasitemia was detected using SM, without clinical signs. He received preemptive therapy with BZ until bone marrow infusion day, with remission of the parasitemia. After ABMT, T. cruzi parasitemia did not relapse nor did the recipient show any clinical signs of CD reactivation.
Group II
Nine chagasic Allo-BMT recipients were included (Table 3 , patients 1-9). In four of them, CD recurrences were diagnosed by SM at days þ 16, þ 101, þ 120 and þ 178 (mean7s.d.: 103.75767.04) after transplant. This last patient also showed skin lesions characterized by inflammatory panniculitis with T. cruzi amastigotes in the biopsy samples. BZ treatment was administered for at least 30 days to all patients, and parasitemia cleared off during the first 14 days of antiparasitic treatment in all of them, with posterior regression of cutaneous lesions as well. No new CD reactivations were manifested in this group until the time of this report.
Group III
The only CD recipient who received an Allo-BMT from CD donor did not relapse (Table 3 , recipient #10).
Group IV
Three non-CD recipients received Allo-BMT from T. cruziinfected donors (Table 3 , patients 11-13). In order to decrease the subclinical T. cruzi parasitemia, primary prophylaxis with BZ was administered to two donors during 30 days before bone marrow infusion. The criterion to administer prophylaxis in CD donors was only the serological reactivity against T. cruzi. In all recipients, transmission of T. cruzi infection through bone marrow did not occur till the date of this report either in serological, parasitological or clinical studies. Furthermore, the third patient in whom the donor did not receive BZ prophylaxis due to emergency, transplantation did not develop primary CD either.
The length of follow-up in groups II, III and IV was 411.387585.26 days (mean7s.d.).
Six ABMT and five Allo-BMT recipients (Tables 2 and  3) were also monitored with hemoculture and xenodiagnosis when this protocol started. Those methods were Table 2 Baseline and follow-up of Chagas disease recipients subjected to autologous BMT negative during the follow-up in all patients, except the above-mentioned ABMT recipient #1 (Table 2) . Acute and chronic GVHD (grades 1-3) were diagnosed in nine out of 10 Allo-CD patients (groups II and III), who were treated with steroids and CsA. Three of those nine GVHD patients relapsed into CD.
It is worth noting that CD reactivation was always associated with complete remission of underlying diseases.
During follow-up, one out of 11 ABMT-CD recipients ( Table 2 , patient #6) and four out of eight AlloCD-BMT (Table 3 , patients #2, 4, 5 and 10) showed negativization of previously reactive CD serology, and there were no CD reactivation events.
The patients did not show bone marrow toxicity or other adverse effects associated to BZ, and hematopoietic recovery was uneventful.
Discussion
Although in developed countries CD has historically been considered an exotic disease, at present, due to migrations, CD has become a serious public health hazard in industrialized countries. Recent estimates indicate that in the US, there is a population of around 7 million people coming in from countries where CD is endemic, 19 and an estimated 100 000-370 000 people are assumed to be affected by CD. 20 In a recent report, three US cases of acute CD following solid-organ transplantation from a single donor were described. In them, the diagnosis of primary infection was done by T. cruzi-positive blood smears and blood cultures. After treatment with Nifurtimox (Lampit s , Bayer Lab) -a drug unavailable in Latin America at present -one patient recovered, while the other two cases had fatal outcomes. One of these patients died of sepsis and hepatic renal failure, and the other of recurrent CD. The specific nifurtimox therapy did not seem to be capable of controlling the infection after a 4-month course of the drug in this last patient. 21 Heart and bone marrow transplants associated with CD were also reported in the US 22 and Spain. 23 In this report, we included all patients submitted to BMT in four centers from Argentina; all patients were monitored with the same prospective protocol during a 10-year period in order to evaluate if the preemptive therapy strategy was an effective approach to detect early CD reactivation (Dictar et al, 10 Altclas et al, 11 and E Efron, R Jorda´n and J Martinez, unpublished data) or CD primary infection.
In the early stages of this study, we also used enriched parasitological tests such as hemoculture and xenodiagnosis, besides the SM, in order to cover all potentially parasitological outcomes likely to occur during the followup of CD-BMT recipients. Those methods were always negative in patients monitored with them, without influencing the outcome or medical therapy in those recipients. Those results persuaded us to rule out those methods from the protocol due to their lack of sensitivity to diagnose CD reactivation or primary infections.
A total of 25 patients with CD were included; of these, 22 were chagasic recipients who underwent ABMTs (n ¼ 12) Table 3 Baseline and follow-up of T. cruzi reactive and non reactive recipients subjected to allogenic BMT or Allo BMTs (n ¼ 10). Association between non-CD recipients and CD donors was present in three patients. The incidence of CD in the four centers was 1.8% with a range of 0.6-3.7%. Reactivation of CD was detected in two out of 12 (16.6%) ABMT recipients (Group 1). Our first patient showed T. cruzi-positive hemoculture 4 days before bone marrow infusion during the neutropenic period, although high levels of T. cruzi parasitemia had never been detected by the direct SM. At that time, this early finding was considered a possible risk of CD reactivation. BZ therapy was administered and parasitemia cleared off with recovery of the patient. Given our present knowledge, and in line with a previous comment about that method, this early positive hemoculture should call for a more careful monitoring in order to detect increment in parasitemia levels through direct SM 10 before the administration of antiparasitic treatment. More recently, patient #10 evidenced reactivation of the disease after severe immunosuppression due to underlying disease near the date of the ABMT. BZ also proved to be successful to recover the patient, and no new CD relapses occurred after BMT. This clinical situation, similar to others published in reports 5, 24 emphasizes the relevance of monitoring CD patients who receive immunosuppressive therapy for underlying disease or transplantation.
Reactivation of CD in four out of 10 (40%) Allo-BMT recipients (Groups II), manifesting with high parasitemia in all patients and also cutaneous lesions in one of them, was higher in ABMT (Group I), which was 16% to the date of this report, than those observed in renal 15 and liver transplantation. [25] [26] [27] The higher tendency to CD reactivation in BMT recipients, six out of 22 patients (27.3%), could be related to the degree of immunosuppression due to underlying diseases or transplantation. Moreover, in Allo-BMT, the intensity of the chemotherapy and/or radiotherapy plus the use of immunosuppressive drugs to avoid GVHD may have increased the risk of CD reactivation episodes in comparison to ABMT and solid-organ transplantation. Most Allo-BMT patients suffered GVHD to different degrees. However, it was not possible to establish any relationship between the reactivation of CD and GVHD, probably due to the small number of patients. Nevertheless, recommendations suggest that when it is necessary to increase the dose of immunosuppressive therapy for underlying diseases or rejection, CD monitoring should be more frequently performed in CD recipients.
It is worth mentioning that in our population, the three non-CD recipients (Group IV) did not suffer the transmission of T. cruzi infection. Two of the living related donors received prophylaxis with BZ for 30 days. Previous experiences in kidney 15 and liver transplants [25] [26] [27] suggest that grafts from CD donors have the potential to transmit CD infection. The experience gained in these previous studies sustained the suggestion of applying prophylaxis in CD-related living donors due to the importance of decreasing the potential inocula of T. cruzi parasites through the organ, in this case, the bone marrow. It is important to note that prophylaxis in CD-related living donors was administered only with serological diagnosis of CD. This criterion was based on the knowledge that chronic CD patients always have subclinical levels of T. cruzi parasitemia and indirect parasitological methods such as xenodiagnosis and hemoculture are low sensitivity tests (o50%) to systematically demonstrate those low values of parasitemia, thus a negative result does not mean absence of parasitemia. PCR could be an important tool to demonstrate parasitemia in the chronic phase, but up till now, it has not been applied in routine medical activity. Additionally, in CD recipients, the presence of blood T. cruzi parasites for those methods does not predict reactivation episodes either.
SM proved to be a useful test for monitoring the levels of T. cruzi parasites in reactivation episodes in our BMT patients. High levels of parasitemia were detected in six patients. The diagnosis of T. cruzi parasites in blood and in tissue biopsies emphasized the relevance of searching for parasites in CD reactivation or infectious episodes. 15 Moreover, the lack of modifications of serological titers observed in reactivation cases, also found in kidney transplantation, 15 suggests that serology is not useful to monitor those reactivation episodes.
This approach, preemptive CD therapy, is based on carefully selected clinical laboratory data, which is considered a predictive tool in clinical or subclinical disease, where the early BZ therapy was useful to avoid the development of systemic replication of parasites in tissue. 28, 29 Such a strategy seems to also have been successful in the management of different infectious diseases that complicate immunosuppressive states as fungal and CMV infections. 30, 31 It would be interesting to emphasize that in different infectious processes associated to BMT, it should be a priority to search for early laboratory data as a predictive tool of clinical disease.
Universal prophylaxis with BZ was never applied in our BMT and CD recipients. In our experience, BZ must be administered only when subclinical or clinical manifestations of CD are present. Previous studies have demonstrated that prophylaxis has not been effective in preventing reactivation of CD in chagasic recipients who underwent heart transplantation. 8 On the other hand, severe side effects associated to BZ therapy were described in a high percentage of adult immunocompetent CD patients, although signs of bone marrow toxicity -a severe side effect associated to this drug -were not observed in our BMT recipients.
In our experience, BZ preemptive or therapeutic therapy must be applied according to the protocol here described, when subclinical or clinical manifestations of CD are present. On the other hand, reactivation of CD did not seem to influence the outcome of underlying diseases in BMT patients. Note that, in our report, all CD recipients with reactivation of the disease showed complete remission of underlying diseases.
Recommendation to administer BZ for at least 30 days in reactivated CD recipients was adequate to clear parasitemia and prevent new relapses in BMT chagasic recipients. Systematic parasitological controls must be performed along with follow-ups to avoid recurrences of CD due to the suppressive, nonsterilizing effect of the parasitemia due to BZ.
At present, it is not known what kind of characteristics of T. cruzi parasites and/or the host or moreover the interrelationship between them, predict the outcome of CD. Variability of clinical outcomes in CD, in this report, that is, reactivation or infection events, is associated to the heterogeneity of T. cruzi, which was recently characterized as belonging to major phylogenetic groups I and II. Group I is prevalent in the southern area of South America and is related to pathological outcomes of chronic CD, and group II is more confined to the Northern part of South America and Central America and involves the jungle cycle of infection mainly in animals as marsupials. So far, although a great deal of evidence is being accumulated to characterize the different clinical phenotypes of T. cruzi strains -as virulence factors,distinct gene/antigens expression, molecules associated with invasion of host tissue, etc -major basic and clinical research is necessary to elucidate different clinical outcomes in CD due to the specific characteristics of T. cruzi parasites 32, 33 The data reported herein show our experience with CD and BMT in four health care centers from Argentina, and prove the relevance of monitoring reactivation or infection events along the evolution in BMT patients; the data also emphasize that CD is a controllable risk for patients undergoing BMT.
